IL-23 Induces Atopic Dermatitis-Like Inflammation Instead of Psoriasis-Like Inflammation in CCR2-Deficient Mice

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Bromley, Shannon K ^a   Larson, Ryan P ^b,c   Ziegler, Steven F ^b,c   Luster, Andrew D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR2; INTERLEUKIN 13; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; THYMIC STROMAL LYMPHOPOIETIN; CCR2 PROTEIN, MOUSE; CYTOKINE; LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOPIC DERMATITIS; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE SEVERITY; EOSINOPHIL COUNT; GENOTYPE; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INFLAMMATION; KERATINOCYTE; MAST CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSORIASIS; TH2 CELL; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; EOSINOPHIL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; NEUTROPHIL; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DERMATITIS, ATOPIC; DISEASE MODELS, ANIMAL; EOSINOPHILS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERLEUKIN-23; INTERLEUKIN-4; LIGANDS; MAST CELLS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEUTROPHILS; PSORIASIS; RECEPTORS, CCR2; SIGNAL TRANSDUCTION;

EID: 84874621078     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058196     Document Type: Article

References (66)

1. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, et al. (1995) Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature medicine 1: 442-447.
2. Szabo SK, Hammerberg C, Yoshida Y, Bata-Csorgo Z, Cooper KD, (1998) Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: localization to both CD4+ and CD8+ subsets. The Journal of investigative dermatology 111: 1072-1078.
3. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, et al. (2008) Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. The Journal of investigative dermatology 128: 1207-1211.
4. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, et al. (2004) Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. The Journal of experimental medicine 199: 125-130.
5. Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB, (2006) In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. Journal of immunology 176: 1908-1915.
6. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, et al. (2007) Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nature immunology 8: 950-957.
7. Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, et al. (2006) IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. The Journal of experimental medicine 203: 2577-2587.
8. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, et al. (2007) Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445: 648-651.
9. Hedrick MN, Lonsdorf AS, Shirakawa AK, Richard Lee CC, Liao F, et al. (2009) CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. The Journal of clinical investigation 119: 2317-2329.
10. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, et al. (2012) Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. The New England journal of medicine 366: 1190-1199.
11. Papp KA, Reid C, Foley P, Sinclair R, Salinger DH, et al. (2012) Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized, Placebo-Controlled Trial. The Journal of investigative dermatology.
12. Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, et al. (2012) Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. The New England journal of medicine 366: 1181-1189.
13. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, et al. (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371: 1665-1674.
14. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, et al. (2007) A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. The New England journal of medicine 356: 580-592.
15. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, et al. (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371: 1675-1684.
16. Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, et al. (2008) Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Archives of dermatology 144: 200-207.
17. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, et al. (2007) Phenotypic and functional features of human Th17 cells. The Journal of experimental medicine 204: 1849-1861.
18. Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, et al. (2007) Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. The Journal of experimental medicine 204: 2803-2812.
19. Singh SP, Zhang HH, Foley JF, Hedrick MN, Farber JM, (2008) Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. Journal of immunology 180: 214-221.
20. Pene J, Chevalier S, Preisser L, Venereau E, Guilleux MH, et al. (2008) Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. Journal of immunology 180: 7423-7430.
21. Homey B, Dieu-Nosjean MC, Wiesenborn A, Massacrier C, Pin JJ, et al. (2000) Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. Journal of immunology 164: 6621-6632.
22. Sato W, Aranami T, Yamamura T, (2007) Cutting edge: Human Th17 cells are identified as bearing CCR2+CCR5- phenotype. Journal of immunology 178: 7525-7529.
23. Lim HW, Lee J, Hillsamer P, Kim CH, (2008) Human Th17 cells share major trafficking receptors with both polarized effector T cells and FOXP3+ regulatory T cells. Journal of immunology 180: 122-129.
24. Rose CE Jr, Sung SS, Fu SM, (2003) Significant involvement of CCL2 (MCP-1) in inflammatory disorders of the lung. Microcirculation 10: 273-288.
25. Charo IF, (1999) CCR2: from cloning to the creation of knockout mice. Chemical immunology 72: 30-41.
26. Gillitzer R, Wolff K, Tong D, Muller C, Yoshimura T, et al. (1993) MCP-1 mRNA expression in basal keratinocytes of psoriatic lesions. The Journal of investigative dermatology 101: 127-131.
27. Deleuran M, Buhl L, Ellingsen T, Harada A, Larsen CG, et al. (1996) Localization of monocyte chemotactic and activating factor (MCAF/MCP-1) in psoriasis. Journal of dermatological science 13: 228-236.
28. Izikson L, Klein RS, Charo IF, Weiner HL, Luster AD, (2000) Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. The Journal of experimental medicine 192: 1075-1080.
29. Fife BT, Huffnagle GB, Kuziel WA, Karpus WJ, (2000) CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. The Journal of experimental medicine 192: 899-905.
30. Rampersad RR, Tarrant TK, Vallanat CT, Quintero-Matthews T, Weeks MF, et al. (2011) Enhanced Th17-cell responses render CCR2-deficient mice more susceptible for autoimmune arthritis. PloS one 6: e25833.
31. Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, et al. (2003) Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nature medicine 9: 40-46.
32. Li J, Li X, Zhang Y, Zhou XK, Yang HS, et al. (2010) Gene therapy for psoriasis in the K14-VEGF transgenic mouse model by topical transdermal delivery of interleukin-4 using ultradeformable cationic liposome. The journal of gene medicine 12: 481-490.
33. Zhang Y, Li J, Liu CY, Zhou XK, Qiu J, et al. (2010) A novel transdermal plasmid-dimethylsulfoxide delivery technique for treatment of psoriasis. Dermatology 221: 84-92.
34. Sato N, Ahuja SK, Quinones M, Kostecki V, Reddick RL, et al. (2000) CC chemokine receptor (CCR)2 is required for langerhans cell migration and localization of T helper cell type 1 (Th1)-inducing dendritic cells. Absence of CCR2 shifts the Leishmania major-resistant phenotype to a susceptible state dominated by Th2 cytokines, b cell outgrowth, and sustained neutrophilic inflammation. The Journal of experimental medicine 192: 205-218.
35. Kim Y, Sung S, Kuziel WA, Feldman S, Fu SM, et al. (2001) Enhanced airway Th2 response after allergen challenge in mice deficient in CC chemokine receptor-2 (CCR2). Journal of immunology 166: 5183-5192.
36. Abdi R, Means TK, Ito T, Smith RN, Najafian N, et al. (2004) Differential role of CCR2 in islet and heart allograft rejection: tissue specificity of chemokine/chemokine receptor function in vivo. Journal of immunology 172: 767-775.
37. Boring L, Gosling J, Chensue SW, Kunkel SL, Farese RV Jr, et al. (1997) Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. The Journal of clinical investigation 100: 2552-2561.
38. Means TK, Hayashi F, Smith KD, Aderem A, Luster AD, (2003) The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. Journal of immunology 170: 5165-5175.
39. Sadik CD, Luster AD, (2012) Lipid-cytokine-chemokine cascades orchestrate leukocyte recruitment in inflammation. Journal of leukocyte biology 91: 207-215.
40. Islam SA, Chang DS, Colvin RA, Byrne MH, McCully ML, et al. (2011) Mouse CCL8, a CCR8 agonist, promotes atopic dermatitis by recruiting IL-5+ T(H)2 cells. Nature immunology 12: 167-177.
41. Chung Y, Yang X, Chang SH, Ma L, Tian Q, et al. (2006) Expression and regulation of IL-22 in the IL-17-producing CD4+ T lymphocytes. Cell research 16: 902-907.
42. Hamid Q, Boguniewicz M, Leung DY, (1994) Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. The Journal of clinical investigation 94: 870-876.
43. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA, (2004) New insights into atopic dermatitis. The Journal of clinical investigation 113: 651-657.
44. Daugherty BL, Siciliano SJ, DeMartino JA, Malkowitz L, Sirotina A, et al. (1996) Cloning, expression, and characterization of the human eosinophil eotaxin receptor. The Journal of experimental medicine 183: 2349-2354.
45. Ponath PD, Qin S, Ringler DJ, Clark-Lewis I, Wang J, et al. (1996) Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. The Journal of clinical investigation 97: 604-612.
46. Luster AD, (1998) Chemokines-chemotactic cytokines that mediate inflammation. The New England journal of medicine 338: 436-445.
47. Nakagome K, Imamura M, Kawahata K, Harada H, Okunishi K, et al. (2011) High expression of IL-22 suppresses antigen-induced immune responses and eosinophilic airway inflammation via an IL-10-associated mechanism. Journal of immunology 187: 5077-5089.
48. Nograles KE, Zaba LC, Shemer A, Fuentes-Duculan J, Cardinale I, et al. (2009) IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. The Journal of allergy and clinical immunology 123: 1244-1252 e1242.
49. Guttman-Yassky E, Nograles KE, Krueger JG, (2011) Contrasting pathogenesis of atopic dermatitis and psoriasis-part II: immune cell subsets and therapeutic concepts. The Journal of allergy and clinical immunology 127: 1420-1432.
50. Pan G, French D, Mao W, Maruoka M, Risser P, et al. (2001) Forced expression of murine IL-17E induces growth retardation, jaundice, a Th2-biased response, and multiorgan inflammation in mice. Journal of immunology 167: 6559-6567.
51. Fort MM, Cheung J, Yen D, Li J, Zurawski SM, et al. (2001) IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 15: 985-995.
52. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, et al. (2002) Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nature immunology 3: 673-680.
53. Zhou B, Comeau MR, De Smedt T, Liggitt HD, Dahl ME, et al. (2005) Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nature immunology 6: 1047-1053.
54. Paul WE, Seder RA, (1994) Lymphocyte responses and cytokines. Cell 76: 241-251.
55. Traynor TR, Kuziel WA, Toews GB, Huffnagle GB, (2000) CCR2 expression determines T1 versus T2 polarization during pulmonary Cryptococcus neoformans infection. Journal of immunology 164: 2021-2027.
56. Nakano H, Lin KL, Yanagita M, Charbonneau C, Cook DN, et al. (2009) Blood-derived inflammatory dendritic cells in lymph nodes stimulate acute T helper type 1 immune responses. Nature immunology 10: 394-402.
57. Kashyap M, Rochman Y, Spolski R, Samsel L, Leonard WJ, (2011) Thymic stromal lymphopoietin is produced by dendritic cells. Journal of immunology 187: 1207-1211.
58. Spadoni I, Iliev ID, Rossi G, Rescigno M, (2012) Dendritic cells produce TSLP that limits the differentiation of Th17 cells, fosters Treg development, and protects against colitis. Mucosal immunology 5: 184-193.
59. Sokol CL, Barton GM, Farr AG, Medzhitov R, (2008) A mechanism for the initiation of allergen-induced T helper type 2 responses. Nature immunology 9: 310-318.
60. Omori M, Ziegler S, (2007) Induction of IL-4 expression in CD4(+) T cells by thymic stromal lymphopoietin. Journal of immunology 178: 1396-1404.
61. Allakhverdi Z, Comeau MR, Jessup HK, Yoon BR, Brewer A, et al. (2007) Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. The Journal of experimental medicine 204: 253-258.
62. Wong CK, Hu S, Cheung PF, Lam CW, (2010) Thymic stromal lymphopoietin induces chemotactic and prosurvival effects in eosinophils: implications in allergic inflammation. American journal of respiratory cell and molecular biology 43: 305-315.
63. Jessup HK, Brewer AW, Omori M, Rickel EA, Budelsky AL, et al. (2008) Intradermal administration of thymic stromal lymphopoietin induces a T cell- and eosinophil-dependent systemic Th2 inflammatory response. Journal of immunology 181: 4311-4319.
64. Yoo J, Omori M, Gyarmati D, Zhou B, Aye T, et al. (2005) Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. The Journal of experimental medicine 202: 541-549.
65. Indramohan M, Sieve AN, Break TJ, Berg RE (2012) Inflammatory monocyte recruitment is regulated by IL-23 during systemic bacterial infection. Infection and immunity.
66. Bogiatzi SI, Fernandez I, Bichet JC, Marloie-Provost MA, Volpe E, et al. (2007) Cutting Edge: Proinflammatory and Th2 cytokines synergize to induce thymic stromal lymphopoietin production by human skin keratinocytes. Journal of immunology 178: 3373-3377.